CD96 Protein (CD96) (AA 22-503) (Fc Tag)

Produktnummer ABIN6253540

Produktdetails

Target: CD96

Protein-Typ: Recombinant

Biologische Aktivität: Active

Proteineigenschaft: AA 22-503

Spezies: Human

Quelle: HEK-293 Cells

Aufreinigungstag / Konjugat: Dieses CD96 Protein ist gelabelt mit Fc Tag.

Sequenz: AA 22-503

Produktmerkmale: This protein carries a mouse IgG2a Fc tag at the C-terminus. The protein has a calculated MW of 80.6 kDa. The protein migrates as 32 KDa, 34 KDa and 120 KDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Reinheit: >90 % as determined by reduced SDS-PAGE.

Endotoxin-Niveau: Less than 0.1 EU per μg by the LAL method.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Buffer: Tris with Glycine, Arginine and NaCl,  pH 7.5

Handhabung: Please avoid repeated freeze-thaw cycles.

Lagerung: -20 °C

Antigendetails

Target: CD96

Andere Bezeichnung: CD96 (CD96 Produkte)

Synonyme: 1700109I12Rik Protein, Tactile Protein, TACTILE Protein, CD96 antigen Protein, CD96 molecule Protein, Cd96 Protein, CD96 Protein

Hintergrund: The progression of pancreatic cancer (PC) is significantly associated with tumor immune escape, which may be associated with nature killer (NK) cell dysfunction. CD226, CD96, and TIGIT, which share the ligand CD155, play important roles in the regulation of NK cell function. The present study was conducted to investigate the roles of these molecules in NK cells from PC patients. TIGIT and CD96 together with the co-stimulatory receptor CD226 form a pathway that is analogous to the CD28/CTLA-4 pathway, in which shared ligands and differential receptor:ligand affinities fine-tune the immune response. Although the roles of TIGIT and CD96 as immune checkpoint receptors in T cell and natural killer cell biology are just beginning to be uncovered, accumulating data support the targeting of these receptors for improving anti-tumor immune responses. A clear understanding of the immune cell populations regulated by TIGIT and CD96 is key to the design of immunotherapies that target these receptors in combination with other existing immune checkpoint blockade therapies. The dysfunction of CD96 may trigger C syndrome: A syndrome characterized by trigonocephaly, severe mental retardation, hypotonia, variable cardiac defects, redundant skin, and dysmorphic facial features, including upslanted palpebral fissures, epicanthal folds, depressed nasal bridge, and low-set, posteriorly rotated ears.

Molekulargewicht: 80.4 kDa

NCBI Accession: NP_005807